PCM
GRTX

Prelude Capital Management’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Prelude Capital Management’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-558
Closed -$7K – 2152
2019
Q4 		$7K Buy
+558
New +$6.8K ﹤0.01% 1745

Other funds holding GRTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Prelude Capital Management's GRTX Position: Q1 2020 in Review

Prelude Capital Management sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q1 2020, closing a stake of 558 shares — an estimated $7K sold.

Prelude Capital Management first reported a position in GRTX in Q4 2019 and held it in 1 quarter. The position peaked at $7K in Q4 2019. 34 funds tracked by Wall St. Rank hold GRTX as of Q1 2020.

  • Prelude Capital Management reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 558 Galera Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $7K.
  • Prelude Capital Management first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Prelude Capital Management's Galera Therapeutics, Inc. Common Stock position peaked at $7K in Q4 2019.
  • 34 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.